# US 2010/0266627 A1 · Allelic exchange mutagenesis in map

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0266627 A1
- Document ID: US20100266627A1
- Status: Published application
- Kind: A1
- Application number: 12/668,651
- Filed: 2008-07-14
- Published: 2010-10-21
- Earliest claimed: 2007-07-12
- Assignees: Washington State University
- Inventors: William C. Davis; Mary Jo Hamilton; John Dahl; Kun Taek Park
- Web page: https://patentgrep.com/patent/US20100266627A1

## CPC

- C12N 15/102: {Mutagenizing nucleic acids}
- A61K 39/04: Mycobacterium, e.g. Mycobacterium tuberculosis
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 37/04: Immunostimulants
- C12N 1/205: Bacterial isolates
- A61K 2039/522: {avirulent or attenuated}
- C12R 2001/325: Mycobacterium avium
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12R: INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS

## Abstract

Particular aspects provide efficient allelic exchange methods to generate directed mutations within genes of slow-growing stains of mycobacteria (e.g., Mycobacterium avium subsp. paratuberculosis (Map), Map 10 or GFP-expressing Map K-10) using a phage-delivery system, and demonstrate high efficiency allelic exchange. Additional exemplary aspects provide non-naturally occurring slow-growing strains of mycobacteria (e.g., Map, M. bovis, M. tuberculosis) having at least one gene deletion (e.g., pknG, relA, lsr2, panC, panD, proC, trpD, sapM (MAP3432), lysA_1, leuD, and leuC, and deletion mutants at the orthologous loci of two known virulence genes in pathogenic mycobacteria (relA and pknG) and one gene related to colony morphology and biofilm formation in fast growing mycobacteria (lsr2) were made. Further aspects provide novel vaccines comprising such deletion mutants, or portions thereof, and methods for making said vaccines. Yet further aspects provide methods for protecting a mammal from virulent Map, M. bovis, or M. tuberculosis, comprising treating the mammal with the inventive vaccines.

## Claims

### Claim 1

A method for directed allelic exchange mutagenesis of slow-growing mycobacterium (sp), comprising:
providing a conditionally replicating transducing mycobacteriophage containing an allelic exchange substrate (AES), the AES comprising a selectable gene flanked by upstream and downstream homologous regions that flank a target locus or gene;
culturing a slow-growing mycobacteria strain characterized by clumping during culturing, followed by gravity sedimentation, low-speed centrifugation to provide a low-speed mycobacteria pellet, and resuspension of the low-speed mycobacteria pellet in culture medium suitable for transducing;
culturing the resuspended slow-growing mycobacteria strain in the presence of the transducing mycobacteriophage at a non-permissive temperature;
depleting bacterial clumps by vigorously shaking the cultures, followed low-speed centrifugation to provide a low-speed mycobacteria pellet, and resuspending of the low-speed mycobacteria pellet in a culture medium or buffer;
withdrawing an amount of the resuspension; and
selecting, using the withdrawn amount and a suitable selection medium, allelic exchange mutants of the slow-growing mycobacteria strain.

### Claim 2 (depends on 1)

The method of claim 1, wherein the slow-growing strain of mycobacteria is Mycobacterium avium subsp. paratuberculosis (Map), Map K10, Mycobacterium bovis, or Mycobacterium tuberculosis.

### Claim 3 (depends on 1)

The method of claim 1, wherein the selectable gene is hygromycin resistant (HygR).

### Claim 4 (depends on 1)

The method of claim 1, wherein the selectable gene is flanked by site-specific resolvase sites.

### Claim 5 (depends on 3)

The method of claim 3, wherein the selection medium comprises at least 75 μg/ml hygromycin.

### Claim 6 (depends on 1)

The method of claim 1, comprising culturing of the slow-growing strain of mycobacteria strain in a medium containing a nonionic surfactant and/or emulsifier, followed by washing the cultured mycobacteria to remove the nonionic surfactant and/or emulsifier prior to culturing in the presence of the transducing mycobacteriophage.

### Claim 7 (depends on 6)

The method of claim 6, wherein the nonionic surfactant and/or emulsifier comprises polysorbate 80.

### Claim 8 (depends on 1)

The method of claim 1, wherein the target gene is at least one selected from the group of genes consisting of pknG, relA, lsr2, panC, panD, proC, trpD, sapM (MAP3432), lysA—1, leuD, and leuC.

### Claim 9 (depends on 1)

The method of claim 1, wherein the allelic exchange frequency is a least 75% for a transduction frequency of 9.5×10−8 to 1.6×10−7.

### Claim 10 (depends on 1)

The method of claim 1, further comprising confirmation of the allelic exchange mutants using at least one of polymerase chain reaction (PCR), nucleic acid sequencing, and RNA expression analysis.

### Claim 11 (depends on 1)

A method for preparing a vaccine composition, comprising:
obtaining an allelic exchange mutant of a slow-growing strain of mycobacteria derived by a method according to claim 1; and
generating a vaccine using the allelic exchange mutant, or a portion thereof.

### Claim 12 (depends on 11)

The method of claim 11, wherein deriving the vaccine comprises use of the allelic exchange mutant, or the portion thereof, to prepare a recombinant Mycobacterium avium sbsp paratuberculosis, M. bovis or M. bovis Bacille Calmette-Guérin (BCG), or M. tuberculosis-based vaccine

### Claim 13 (depends on 11)

The method of claim 11, wherein the vaccine comprises a live-attenuated vaccine.

### Claim 14 (depends on 11)

A vaccine composition comprising a non-naturally occurring mycobacteria mutant prepared by the methods of claim 11, or a portion of said mutant, in a pharmaceutically acceptable carrier or excipient, wherein the vaccine is suitable to protect a mammal from challenge by a virulent mycobacterium.

### Claim 15 (depends on 14)

The vaccine composition of claim 14, wherein the virulent mycobacterium is Mycobacterium avium subsp. paratuberculosis (Map), M. bovis, or M. tuberculosis.

### Claim 16 (depends on 14)

The vaccine composition of claim 14, wherein the mammal is a cow, human, or human child.

### Claim 17 (depends on 14)

The vaccine composition of claim 14, wherein the slow-growing strain of mycobacteria is Mycobacterium avium subsp. paratuberculosis (Map), Map K10, Mycobacterium bovis, or Mycobacterium tuberculosis.

### Claim 18 (depends on 17)

The vaccine of claim 17, wherein the slow-growing strain of mycobacteria is Mycobacterium avium subsp. paratuberculosis (Map), and wherein the target gene is at least one selected from the group consisting of pknG, relA, lsr2, panC, panD, proC, trpD, sapM (MAP3432), lysA—1, leuD, and leuC.

### Claim 19 (depends on 18)

The vaccine of claim 18, wherein the pknG, relA, lsr2, panC, panD, proC, trpD, sapM (MAP3432), lysA—1, leuD, and leuC genes comprise SEQ ID NOS:1, 4, 6, 34, 36, 38, 40, 42, 44, 46 and 48, contiguous portions thereof, or sequences at least 95%, at least 98%, or at least 99% identical thereto, respectively.

### Claim 20 (depends on 14)

The vaccine of claim 14, wherein the vaccine comprises a live-attenuated vaccine.

### Claim 21 (depends on 14)

The vaccine of claim 14, wherein the non-naturally occurring mycobacteria mutant strain further comprises a foreign DNA stably integrated its genomic DNA.

### Claim 22 (depends on 21)

The vaccine of claim 21, wherein the foreign DNA encodes at least one protein or polypeptide selected from the group consisting of an antigen, an enzyme, a lymphokine, an immunopotentiator, and a reporter molecule.

### Claim 23 (depends on 22)

The vaccine of claim 22, wherein the foreign DNA encodes at least one protein antigen selected from the group consisting of antigens from Mycobacterium leprae, Mycobacterium tuberculosis, malaria sporozoites, malaria merozoites, diphtheria toxoid, tetanus toxoids, Leishmania spp., Salmonella spp., Mycobacterium africanum, Mycobacterium intracellulare, Mycobacterium avium, Treponema spp., Pertussis, Herpes virus, Measles virus, Mumps virus, Shigella spp., Neisseria spp., Borrelia spp., rabies, polio virus, Human immunodeficiency virus, snake venom, insect venom, and Vibrio cholera; steroid enzymes; interleukins; tumor necrosis factor alpha and beta.; interferon alpha, beta, and gamma; and reporter molecules GFP, luciferase, beta-galactosidase, beta-glucuronidase and catechol dehydrogenase.

### Claim 24 (depends on 14)

Vaccine of claim 14, wherein the vaccine is for at least one of Johne's disease, paratuberculosis (Ptb), Crohn's disease, and tuberculosis.

### Claim 25 (depends on 1)

A non-naturally occurring allelic exchange mutant of a slow-growing strain of mycobacteria derived by a method according to claim 1.

### Claim 26 (depends on 25)

The non-naturally occurring allelic exchange mutant of claim 25, wherein the slow-growing strain of mycobacteria is Mycobacterium avium, Mycobacterium avium subsp. paratuberculosis (Map), Map K10, Mycobacterium bovis, or Mycobacterium tuberculosis.

### Claim 27 (depends on 25)

The non-naturally occurring allelic exchange mutant of claim 25, wherein the Mycobacterium avium subsp. paratuberculosis (Map) is a GFP-expressing strain of Map K-10.

### Claim 28 (depends on 25)

The non-naturally occurring allelic exchange mutant of claim 25, wherein the slow-growing strain of mycobacteria is Mycobacterium avium subsp. paratuberculosis (Map), and wherein the target gene is at least one selected from the group consisting of pknG, relA, lsr2, panC, panD, proC, trpD, sapM (MAP3432), lysA—1, leuD, and leuC.

### Claim 29

A non-naturally occurring deletion mutant of Mycobacterium avium subsp. paratuberculosis (Map), wherein the Map exhibits attenuated virulence in a mammal when compared to the Map without the deletion.

### Claim 30 (depends on 1, 29)

The non-naturally occurring deletion mutant of claim 29 derived by a method according to claim 1.

### Claim 31 (depends on 29)

The non-naturally occurring deletion mutant of claim 29, wherein the target gene is at least one selected from the group consisting of pknG, relA, lsr2, panC, panD, proC, trpD, sapM (MAP3432), lysA—1, leuD, and leuC.

### Claim 32 (depends on 31)

The non-naturally occurring deletion mutant of claim 31, wherein the target gene is at least one selected from the group consisting of pknG, relA, and lsr2.

### Claim 33 (depends on 31)

The non-naturally occurring deletion mutant of claim 31, wherein the pknG, relA, lsr2, panC, panD, proC, trpD, sapM (MAP3432), lysA—1, leuD, and leuC genes comprise SEQ ID NOS:1, 4, 6, 34, 36, 38, 40, 42, 44, 46 and 48, contiguous portions thereof, or sequences at least 95%, at least 98%, or at least 99% identical thereto, respectively.

### Claim 34 (depends on 15)

A method of protecting a mammal from a virulent Mycobacterium avium subsp. paratuberculosis (Map), M. bovis, or M. tuberculosis, comprising treating the mammal with the vaccine based on the non-naturally occurring deletion mutant of claim 15.

### Claim 35 (depends on 34)

The method of claim 34, wherein the vaccine is administered subcutaneously or intradermally.

### Claim 36 (depends on 29)

A method of protecting a mammal from a virulent Mycobacterium avium subsp. paratuberculosis (Map), M. bovis, or M. tuberculosis, comprising treating the mammal with the deletion mutant of claim 29.
